The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

One significant advancement in endometrial cancer treatment is the combination of lenvatinib, a targeted therapy, with pembrolizumab, an immunotherapy. A recent phase 3 trial demonstrated that ...

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.

If somebody has gone through menopause and then bleeding reappears, it’s really important that the patient does not make ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

Cancer rates are declining, but young women are being diagnosed more frequently. Learn about the current trends and research efforts.

Wright, MD, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Columbia University College of Physicians & Surgeons, The Herbert Irving Comprehensive Cancer Center ...